33 results about "Neutral Charge" patented technology

An OLED device comprises a cathode, a light emitting layer and an anode, in that order, and, has located between the cathode and the light emitting layer, a further layer containing a cyclometallated complex represented by Formula (4′) wherein: Z and the dashed arc represent two or three atoms and the bonds necessary to complete a 5- or 6-membered ring with M; each A represents H or a substituent and each B represents an independently selected substituent on the Z atoms, provided that two or more substituents may combine to form a fused ring or a fused ring system; j is 0-3 and k is 1 or 2; M represents a Group IA, IIA, IIIA and IIB element of the Periodic Table; m and n are independently selected integers selected to provide a neutral charge on the complex; and provided that the complex does not contain the 8-hydroxyquinolate ligand. Such devices exhibit reduce drive voltage while maintaining good luminance.

An OLED device comprises a cathode, a light emitting layer and an anode, in that order, and, has located between the cathode and the light emitting layer, a further layer containing a cyclometallated complex represented by Formula (4′) wherein: Z and the dashed arc represent two or three atoms and the bonds necessary to complete a 5- or 6-membered ring with M; each A represents H or a substituent and each B represents an independently selected substituent on the Z atoms, provided that two or more substituents may combine to form a fused ring or a fused ring system; j is 0-3 and k is 1 or 2; M represents a Group IA, IIA, IIIA and IIB element of the Periodic Table; m and n are independently selected integers selected to provide a neutral charge on the complex; and provided that the complex does not contain the 8-hydroxyquinolate ligand. Such devices exhibit reduce drive voltage while maintaining good luminance.

A drug electrode assembly usefully employed in an electrotransport device for the delivery of drugs across a tissue surface includes an electrode, a drug reservoir which stores the drug (including an ionized (e.g., anionic) or neutrally charged drug species), and a liquid impermeable solid-state assist ion conducting barrier layer interposed between the electrode and the drug reservoir. The barrier layer can be a single-ion conductor of a specific (unique) species of ion called the assist ion. During drug delivery, the assist ion moves across the barrier layer into or out of the drug reservoir, and as the assist ion crosses the barrier layer / drug reservoir interphase, the drug species moves to the tissue surface. The assist ion can be, for example, sodium ions (Na+), and the electrode can be an electrode of the assist ion (i.e., a sodium electrode).

An OLED device comprises a cathode, a light emitting layer and an anode, in that order, and, having located between the cathode and the light emitting layer, a further layer containing;(a) 10 vol % or more of a carbocyclic fused ring aromatic compound, and (b) a cyclometallated complex represented by Formula (4′)wherein:Z and the dashed arc represent two or three atoms and the bonds necessary to complete a 5- or 6-membered ring with M;each A represents H or a substituent and each B represents an independently selected substituent on the Z atoms, provided that two or more substituents may combine to form a fused ring or a fused ring system;j is 0-3 and k is 1 or 2;M represents a Group IA, IIA, IIIA and IIB element of the Periodic Table; andm and n are independently selected integers selected to provide a neutral charge on the complex; andprovided that the complex does not contain the 8-hydroxyquinolate ligand. Such devices exhibit reduce drive voltage while maintaining good luminance.

A drug electrode assembly usefully employed in an electrotransport device for the delivery of drugs across a tissue surface includes an electrode, a drug reservoir which stores the drug (including an ionized (e.g., anionic) or neutrally charged drug species), and a liquid impermeable solid-state assist ion conducting barrier layer interposed between the electrode and the drug reservoir. The barrier layer can be a single-ion conductor of a specific (unique) species of ion called the assist ion. During drug delivery, the assist ion moves across the barrier layer into or out of the drug reservoir, and as the assist ion crosses the barrier layer / drug reservoir interphase, the drug species moves to the tissue surface. The assist ion can be, for example, sodium ions (Na+), and the electrode can be an electrode of the assist ion (i.e., a sodium electrode).

A chemical mechanical polishing composition includes a water based liquid carrier and first and second silica abrasives dispersed in the liquid carrier. The first silica abrasive is a colloidal silica abrasive having a permanent positive charge of at least 10 mV. The second silica abrasive has a neutral charge or a non-permanent positive charge. A method for chemical mechanical polishing a substrate including a tungsten layer includes contacting the substrate with the above described polishing composition, moving the polishing composition relative to the substrate, and abrading the substrate to remove a portion of the tungsten from the substrate and thereby polish the substrate.

A device and a method for printing biomolecules onto a substrate using an electrohydrodynamic (EHD) effect are provided. The device for printing biomolecules onto a substrate using an electrohydrodynamic (EHD) effect includes at least one capillary having an outlet through which a feeding solution of biomolecules selected from the group consisting of nucleic acids, proteins, and oligopeptides is discharged, the nucleic acids being selected from the group consisting of probe DNA, RNA, peptide nucleic acid (PNA), and LNA and the proteins being selected from the group consisting of antigen and antibody; a printer body supporting the at least one capillary; a substrate below the outlet having a target surface onto which the biomolecules are deposited; a first electric field forming electrode located on the printer body around the circumference of the outlet; a second electric field forming electrode spaced apart from the first electrode by a predetermined distance; and a voltage applying unit which is electrically connected to the first electrode and the second electrode to apply an alternating current (AC) voltage between the first electrode and the second electrode so that an electric field may be formed around the biomolecule solution suspended in the outlet, and due to the interaction of the electric field and a difference in dielectric constant between the biomolecule solution having a free surface and the surrounding atmosphere, the electric force acts inward on the biomolecule solution from the surroundings, thereby dropping a predetermined amount of the biomolecule solution onto the target surface of the substrate. By using an EHD effect, the advantages of the device and method are that the process is quick, the biomolecule spots are uniform and easily aligned, and especially it is possible to spot the biomolecules correctly and reproducibly even when the printer body is not fully aligned with the substrate. In addition, the device and method are applicable to proteins which are sensitive to heat and biomolecules which have neutral charges.

The invention discloses a method of improving directional imaging ability of carbon dots to cell nucleolus. The method includes: using citric acid and ethylene diamine as carbon sources to prepare carbon dots; adjusting the surfaces of the carbon dots from negative charge to close to neutral so as to improve directional imaging ability of the carbon dots to the cell nucleolus. Common organic saltis used as a carbon source and simply treated to prepare the carbon dots. Effect of the carbon dots on nucleolus imaging is improved by changing charge on the surfaces of the obtained carbon dots, andthe carbon dots with the surfaces in neutral charge have better directional imaging effect on the nucleolus.

The present invention describes rhodamine compounds particularly well-suited for pre-labeling a protein that is then subjected to two-dimensional electrophoresis. Isomeric purification and synthesis of a dye having net neutral charge or no charge precludes interference with isoelectric electrophoretic separation.

Differential surface-charge-dependent localization of nanoceria in normal cells and cancer cells plays a critical role in the toxicity profile of a nanoceria particle. Engineered surface-coated cerium oxide nanoparticles with different surface charges that are positive, negative and neutral provide therapeutic results for normal and cancer cell lines. Results show that nanoceria with a positive or neutral charge enters most of the cell lines studied, while nanoceria with a negative charge internalizes mostly in the cancer cell lines. Moreover, upon entry into the cells, nanoceria is localized to different cell compartments (e.g. cytoplasm and lysosomes) depending on the nanoparticle surface charge. The internalization and subcellular localization of nanoceria plays a key role in the nanoparticle cytotoxicity profile, exhibiting significant toxicity when they localize in the lysosomes of the cancer cell lines. In contrast, minimal toxicity is observed when they localize into the cytoplasm or do not enter the cells.

The intelligent leakage circuit breaker is mainly composed of: digital logic microcontroller A, fault sensing circuit B, electromagnetic trip circuit C, low-voltage power circuit D, ground circuit PE, accessories F, etc. Using digital logic microcontroller control, with leakage protection function, it also innovates the failure of ungrounded wire, live ground wire, live neutral wire, neutral wire and phase wire, and single-phase misconnection and two-phase faults in the controlled circuit. The intelligent and advanced protection function of non-electric shock protection can fundamentally eliminate electric shock and electrical fire between people. The invention has little power consumption, low cost and volume no larger than the existing leakage circuit breaker, and is a replacement product of the existing leakage circuit breaker.

The present invention relates to relates to a nanoparticle that includes a shell formed from a first monomer having a first charge and a second monomer different than the first monomer. The first and second monomers are copolymerized, and the shell encapsulates a core region and is associated with a charged entity having a second charge of opposite sign to the first charge. The present invention further relates to a nanoparticle having a neutral charge. The present invention further relates to nanoparticle dispersions, methods of making the nanoparticle, methods of method of imaging, methods of delivering drugs, and methods of delivering a high concentration of contrast enhancing and / or imaging agents.

The invention discloses a supercritical / sub-critical water blocking method of HPLC (High Performance Liquid Chromatography) reversed phase bonded stationary phase, which comprises the steps of using carbon dioxide supercritical fluid and / or carbon dioxide sub-critical fluid as a carrier, bring a blocking reagent and a catalyst into a supercritical / sub-critical fluid reactor loaded with silica gel reversed phase bonded stationary phase, and carrying out blocking reaction under a closed condition. According to the method, residual active silanol groups can be thoroughly closed, and lyophobic reversed phase bonded stationary phase with complete neutral charge is produced; no residual active silanol groups exchanges side effects with alkali compound cations, so that alkali compound has a very symmetrical peak shape, and the retention time and mechanism fully follow the order from low to high of hydrophobicity of the compound. The method has the advantages that the reaction condition is mild, the reversed phase bonded stationary phase has no damage, the life of a chromatographic column is long, the repeatability of production batches is very good, the use amount of a toxic organic solvent, such as methylbenzene, is minimized, the pollution to the environment is reduced to the greatest extent, and the process continuity and semi-automatization can be realized.

A hydrophilic silicone, compositions comprising the same, and articles comprising the same are shown and described herein. The hydrophilic silicone is an ionically modified silicone compound wherein the compound has a net neutral charge. The hydrophilic silicone compounds may be provided as part of a composition, e.g., a composition suitable for forming a hydrogel, which may be employed to form afilm material and even an article (e.g., in a contact lens).

A solid oxide fuel cell includes a porous anode, a dense electrolyte in contact with the porous anode, and a porous cathode in contact with the dense electrolyte. The porous cathode is characterized by a single-phase structure of Brownmillerite or Srebrodolskite, the composition thereof having the formula (Ca2-xAx)(Fe2-yBy)O5±z wherein: A is at least one element selected from the group: rare earth elements, Bi, and alkaline elements; B is at least one element selected from the group: Al, Ga, In, Mg, Si, and transition metal elements; 0≦x<2; 0≦y<2; and z is a variable, the value of which is such that the overall composition has a generally neutral charge state.

A composition for forming an electrically conductive antistatic layer comprises: electronically conductive polymer particles; a neutral-charge conductivity enhancer; and a hydrophilic polymeric binder.

The invention provides a nitrogen-containing double-tooth heterocyclic ring substituted tetrazole type rare-earth complex LnL3 expressed by the formula I, wherein Ar is a nitrogen-containing double-tooth heterocyclic ring; the center rare-earth ion Ln is any one of yttrium, lanthanum, cerium, praseodymium, neodymium, samarium, europium, gadolinium, terbium, dysprosium, holmium, erbium, thulium, ytterbium and lutetium. The preparation method of the nitrogen-containing double-tooth heterocyclic ring substituted tetrazole type rare-earth complex LnL3 is characterized in that a nitrogen-containing double-tooth heterocyclic ring substituted tetrazole type three-tooth compound, namely a dipyridyl tetrazole type three-tooth compound or phenanthroline tetrazole type three-tooth compound, is taken as a single ligand, and simultaneously, coordination saturation is satisfied, and the tetrazole group in the complex serves as negative irons to realize electrically neutral charge balance together with center rare-earth metal cations. The obtained rare-earth complex is high in thermal stability, can be prepared into a device through an evaporation film-forming process or a solution film-forming process. Besides, the preparation method has the advantages of high yield, of the product has high purity, reaction time is short and operation is simple; and as a result, the cost is greatly reduced.

In various embodiments, the present invention is a method and apparatus for label-free detection and optional quantification of double-stranded nucleic acid comprising binding a first layer comprising a charged species to a sensing surface having an associated first charge, wherein the first layer confers to the sensing surface a second charge or a neutral charge on a net basis, performing at least one cycle of DNA amplification to produce a double-stranded nucleic acid, and measuring a property of the interaction between the first layer and the double-stranded nucleic acid after the at least one cycle of DNA amplification. The present invention may be used in a cyclic manner, corresponding with the cyclic nature of DNA amplification processes.

Antiviral compositions containing one or more antiviral agents coupled to a polymer and methods of making and using the compositions, are described herein. The one or more antiviral agents are covalently coupled to the polymer, and thereby prevent or decrease development of drug resistance. In some embodiments, the polymer is a biodegradable polymer. In particular embodiments, the polymer is a water-soluble, biodegradable polymer, which has an overall neutral charge (e.g., no charged groups or overall neutral charge). In a more particular embodiment, the neutral polymer is polyglutamine or a polymer having properties similar to polyglutamine, polyaspartate, and other homopolypeptides that can be modified to have no charge or no net charge. The compositions described herein are effective at treating a variety of viral infections, such as influenza, respiratory syncythial virus, rhinovirus, human metaneumovirus, and other respiratory diseases, while inhibiting or preventing the development of resistance.

The invention provides a cell penetrating peptide with neutral charge, wherein the net charge of the cell penetrating peptide under physiological conditions is 0. The invention also provides a specific amino acid sequence. The invention also provides application of the cell penetrating peptide with neutral charge as a delivery carrier in cells, medical application of the cell penetrating peptide with neutral charge as the delivery carrier of therapeutic drugs in cells, and application of the cell penetrating peptide with neutral charge as a contrast agent in the medical imaging technology of the delivery carrier in cells. Furthermore, homologues of the cell penetrating peptide with neutral charge also have cell penetrating performance and can medically serve as the delivery carrier in cells as well as serve as the delivery carrier of the therapeutic drugs in cells.

A colored photosensitive composition containing a dye (A) comprising: a compound indicated by general formula (I); a polymerizable compound (B) having an ethylenically unsaturated bond; and a photopolymerization initiator (C). In the general formula (I), X is ideally an oxygen atom . Furthermore, at least one type of coloring materials (excluding the dye (A)) ideally contains (D). (Refer to the Description for definitions of R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, and X in the formula. Anq- indicates a q-valent anion, q indicates 1 or 2, and p indicates a coefficient for keeping a neutral charge.)

This carrier carries a pigment (A) and a co-adsorbent (B) represented by the following general formula (1). (In the formula, ring A represents a 5- or 6-membered heterocycle which may be further condensed; the hydrogen atom in ring A may be substituted by a hydrocarbon group which may have a substituent, a halogen atom, a cyano group, a nitro group, a —OR2 group, or a —SR2 group; Z represents a divalent aliphatic hydrocarbon group interrupted 0-3 times by —O— or the like; Z1 represents a divalent aromatic group; R1 represents a carboxylic acid group, a sulfonic acid group, a phosphoric acid group, or a phosphonic acid group; R2 and R3 represent a hydrocarbon group which may have a hydrogen atom or a substituent; Anm− represents an m-valent anion; m represents an integer of 1 or 2; and p represents a coefficient for maintaining a neutral electric charge).

An indolium compound is represented by formula (I):Ring A: a benzene or naphthalene ring. Ring B: 5- or 6-membered heterocyclic or aromatic ring. Z: alkyl group having 1-8 carbon atoms, may be substituted with a halogen atom or interrupted by —O—, —CO—, —OCO—, or —COO—, a sulfonyl group having a hydrocarbyl group having -8 carbon atoms, a sulfinyl group having a hydrocarbyl group having 1-8 carbon atoms, an alkylamino group having an alkyl group having 1-8 carbon atoms, a dialkylamino group having alkyl groups having 1-8 carbon atoms, a cyano group, a nitro group, a hydroxyl group, or a halogen group. R1: group represented by formula (II) or (II′). R2: organic group having 1-30 carbon atoms or group represented by formula (II), (II′), or (III). Y: group represented by formula (III). n: integer 0-4; Anm−: m-valent anion, m is 1 or 2. p: coefficient for neutral charge:

The invention provides novel compounds that may serve as anticancer therapeutics. The compounds of the invention bind to polo-like kinases through the polo-box domain. In certain embodiments, the compounds of the invention are POM-protected peptide derivatives. The use of cationic bis-alkyl his residues in combination with a mono POM-protected phophoryl group results in a peptide possessing an overall neutral charge. The peptide derivatives of the invention have achieved both good efficacy and an enhanced bioavailability. The invention also provides methods of use, compositions, and kits thereof. Further, the invention provides a novel method of design and / or synthesis of phosphoryl-derived peptide derivatives useful as therapeutic agents.

Differential surface-charge-dependent localization of nanoceria in normal cells and cancer cells plays a critical role in the toxicity profile of a nanoceria particle. Engineered surface-coated cerium oxide nanoparticles with different surface charges that are positive, negative and neutral provide therapeutic results for normal and cancer cell lines. Results show that nanoceria with a positive or neutral charge enters most of the cell lines studied, while nanoceria with a negative charge internalizes mostly in the cancer cell lines. Moreover, upon entry into the cells, nanoceria is localized to different cell compartments (e.g. cytoplasm and lysosomes) depending on the nanoparticle surface charge. The internalization and subcellular localization of nanoceria plays a key role in the nanoparticle cytotoxicity profile, exhibiting significant toxicity when they localize in the lysosomes of the cancer cell lines. In contrast, minimal toxicity is observed when they localize into the cytoplasm or do not enter the cells.